AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04698109 — intervention group
Intervention type: OTHER
Intervention: Biological sample collection
Description: Collection of faeces, urine, saliva, vaginal swab for biobanking, to evaluate the proteomic, metascriptomic, metabolomic, metagenomic, and metagenetic profile, and to perform routine screening
Study NCT04698109 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Anamnestic questionnaire, 3-day food questionnaire, Food Frequency Questionnaire
Study NCT04698109 — intervention group
Intervention type: OTHER
Intervention: Medical examination
Description: Blood pressure measurement, abdominal and thoracic physical examination
Study NCT06396455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: interscalene block group
Description: The ISB group scanning was done by linear ultrasound probe just below the level of the cricoid cartilage medial to the sternocleidomastoid muscle; the skin was disinfected, and the transducer was positioned in the transverse plane to identify the carotid artery. Once the artery was identified, the transducer was moved slightly laterally across the neck to identify the scalene muscles and the brachial plexus that is present between the anterior and middle scalene muscles. 3 ml lidocaine 1% was injected at puncture site The needle was then inserted in-plane toward the brachial plexus, in a lateral-to-medial direction. After a careful aspiration, 20 ml of bupivacaine 0.25% was injected.
Study NCT06396455 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Suprascapular nerve block group
Description: After cleaning the skin with an antiseptic solution, an ultrasound probe was put in sagittal orientation at the superior medial border of the scapula to identify the pleura and then moved laterally; when it was parallel to the spine of the scapula, the transducer was moved cephalad and the suprascapular fossa was identified, and then the transducer was moved lateral to locate the suprascapular notch. The suprascapular nerve was a round hyperechoic structure beneath the transverse scapular ligament in the scapular notch. 3 ml lidocaine 1% was injected at puncture site then the needle was inserted along the longitudinal axis of the ultrasound beam, and 10 ml of bupivacaine 0.25% was injected.
Study NCT04968353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Incisally-beveled attachment
Description: Incisally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
Study NCT04968353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gingivally-beveled attachment
Description: Gingivally-beveled attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
Study NCT04968353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Optimized attachment
Description: Optimized attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
Study NCT04968353 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal attachment
Description: Horizontal attachments will be bonded to teeth before or during orthodontal treatment with clear aligners
Study NCT04372901 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Digitally constructed frameworks before implant placement
Description: Intervention group in which the edentulous area will be restored with 3-implant screwmented CAD/CAM frameworks constructed based on planned implant positions.
Study NCT04743271 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-Fat Diet
Description: The diet will consist of a breakfast, lunch, dinner, and snack
Study NCT04743271 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-Fat Diet
Description: The diet will consist of a breakfast, lunch, dinner, and snack
Study NCT05525832 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Nasopharyngeal washes with NaCl 0.9%
Study NCT06405165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: student success
Description: The effect of the flipped education-Jigsaw learning model on the knowledge level of urinary catheter care in nursing students.
Study NCT05257590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injection [Opdivo]
Description: Nivolumab will be administered at 240 mg, IV, Q2 weeks with an option for 480 mg, IV, Q4 weeks starting with Cycle 3 if judged to be reasonable by the investigator based on the safety and tolerability.
Study NCT05257590 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVM-1118
Description: CVM-1118 will be administered 200 mg, PO, BID with an option to increase the starting dose to 300 mg, PO, BID for the subsequent subjects following assessment of safety data from the initial 10 subjects.
Study NCT06354348 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: USG, Grip strength, Chair stand test (CST)
Description: Anterior thigh muscle thickness was measured with USG Grip strength was measured with an electronic hand dynamometer Chair stand test (CST) was performed while participants were asked to stand up and sit down from a chair - without arm rest, for five times as quick as possible, with their arms crossed over their chests.
Study NCT05512182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Pembrolizumab : 200mg/Q3W/IV infusion/Day 1of each 3-week cycle Neratinib : Week 1: 120 mg, Week 2: 160 mg, Week 3 and onwards: 240 mg/QD/Oral/Once daily Paclitaxel : 175mg/m2 /Q3W/IV infusion/Day 1of each 3-week cycle
Study NCT05381233 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Gross motor function classification System (GMFCS)
Description: assessment
Study NCT05216718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-flap
Description: Mini-flap BABA robotic-thyroidectomy creates flaps up to the cricoid cartilage
Study NCT05216718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional flap
Description: Conventional flap BABA robotic-thyroidectomy creates flaps up to the thyroid cartilage
Study NCT05381233 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Zarit burden Inventory measure
Description: assessment
Study NCT04372901 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Digitally constructed frameworks after implant placement
Description: Control group: edentulous area will be restored with 3-implant conventional screw retained CAD/CAM frameworks constructed after implant placement.
Study NCT05241912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: administration of dobutamine 0.01 - 0.04 U/min after induction of anesthesia to maintain oxygen delivery
Study NCT05381233 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Arabic Version of Chalder Fatigue Scale (CFQ version 11)
Description: assessment
Study NCT05075694 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Touch
Description: Therapeutic Touch performed in line with the Therapeutic Touch Practice Procedure included the following steps: centering, assessing, rebalancing, reassessing, reexamining, grounding, and closure.
Study NCT05075694 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Therapeutic Touch
Description: The control group was administered STT instead of TT for 10 minutes for successive 5 days. The practice was implemented in line with STTPP. The practice was implemented by not centering or intending to help to heal, by moving at a longer distance, and by imitating the TT practice protocol visually.
Study NCT06387381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSFA
Description: Each subject receives a single intravenous injection of 68Ga-PSFA.
Study NCT04732923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assigned intervention - procedure
Description: This study is defined in 3 stages :~STEP 1 : during the cardiac rehabilitation program over 4 weeks 6 minute walk test, questionnaires~STEP 2 : monitoring at 6 months after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires~STEP 3 : monitoring at one year after cardiac rehabilitation program Nurse interview, 6 minute walk test, questionnaires
Study NCT05370976 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytotect®CP
Description: Cytotect®CP in two phases:~Induction phase: 1 ml/kg/week for 4 weeks Maintenance phase: 1 ml/kg/2 weeks for 12 weeks or corticosteroid dose \< 0.5 mg/kg, according to which condition occurs first.~Patients developing CMV infection under Cytotect®CP must be given standard anti-CMV treatment (Gancyclovir or Foscarnet) according to their center procedure. Cytotect®CP will be maintained
Study NCT05293600 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule 30 min before bedtime
Study NCT05293600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with increased loop gain will be given Acetazolamide 500 mg.
Study NCT05293600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased arousal threshold will be given Trazodone 100 mg.
Study NCT05293600 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atomoxetine and eszopiclone
Description: The intervention drug will be determined based on altered endotype and administered 30 min before bedtime. Patients will only take one drug of this intervention, which will be subsequently compared to placebo. Patients with decreased muscle responsiveness will be given Atomoxetine and Eszopiclone 80 + 3 mg.
Study NCT06094608 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Morning light treatment
Description: Light therapy via the Re-Timer. Participants will conduct light treatment in the mornings at home for one hour using Re-timer®.
Study NCT06094608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment-as-usual
Description: Participants will not make modifications to their activities or sleep schedule.
Study NCT05302973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional rehabilitation
Description: 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
Study NCT05302973 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic exercise
Description: 30 min/day of aerobic exercise added to 1h/day for 5 days/week of conventional rehabilitation for people wtih post-COVID-19
Study NCT06554977 — intervention group
Intervention type: OTHER
Intervention: Laboratory
Description: CBC Kidney function (Urea, creatine) Platelets to albumin ratio Albumin /creatine ratio CRP Urine analysis Abdominal us Kidney function , CBC , Albumin will be done at the time of admission i
Study NCT04701853 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific abdominal muscle training
Description: Specific abdominal muscle training
Study NCT04701853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Care according to each center.
Study NCT06345170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The DIR/Floortime™ Therapy Program
Description: The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
Study NCT06345170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The DIR/Floortime™ Therapy Program
Description: The DIR/Floortime™ therapy program will be applied by the therapist in the clinic for 50 minutes, 2 days a week for 12 weeks
Study NCT06345170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program
Description: The Social-Communication Area Developmental Screening Test for Infants and Young Children (SCASI) Training Program will be applied by the parents at home, 2 days a week, for an average of 30 minutes a day, for 12 weeks
Study NCT04124120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single arterial graft
Description: This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
Study NCT04124120 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multiple arterial grafting
Description: This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
Study NCT06138353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Shuxuening injection or placebo
Description: Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
Study NCT06138353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shuxuening injection or placebo
Description: Shuxuening injection treatment group : Shuxuening injection (specification: 10ml/branch, Lanzhi Group Wanrong Pharmaceutical Co., Ltd.), 20 ml (2 branches) + 5% dextrose injection 250 ml, intravenously, once a day, from the first day of postoperative, treatment for 1 course of treatment, a total of 10-14 days.
Study NCT06181916 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Amp
Description: Amp is a virtual support system mHealth app that provides information and social support to help young Black men who have sex with men (YBMSM) living with HIV achieve better HIV care continuum outcomes and overall well-being.
Study NCT05038618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVC-COV1901(S protein with adjuvant)
Description: Approximately 400 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region
Study NCT06337162 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: 400 mg Tablet
Study NCT06231914 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StarWalker® PQX
Description: Third-generation ASP-powered technology for ultra performance: Highest pico power \& energy, shortest pico pulse width, wide range of laser wavelengths, exceptional spot size capabilities, largest fluence spectrum for flat-top handpieces
Study NCT06278870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disitamab vedotin
Description: disitamab vedotin 2mg/kg iv q2w
Study NCT06278870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: pyrotinib 400mg po q28d
Study NCT06278870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
Study NCT06278870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trastuzumab
Description: trastuzumab 8mg/kg for the first cycle, 6mg/kg for subsequent treatments iv q21d
Study NCT06278870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: pertuzumab 840mg for the first cycle, 420mg for subsequent treatments iv q21d
Study NCT05726448 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth solution
Description: Mobile-friendly nutrition education platform
Study NCT06278870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: taxane drug
Description: Docetaxel/paclitaxel/albumin paclitaxel/liposomal paclitaxel, dosage and administration are determined according to the latest version of the NCCN and CSCO breast cancer guideline recommendations
Study NCT05145803 — intervention group
Intervention type: DEVICE
Intervention: Polyvinylalcohol strip [diagnostic]
Description: The investigators will measure SARS-CoV-2 in exhaled breath of asymptomatic and symptomatic persons using PVA test strips embedded in face masks (FMS) - an innovative, non-invasive method for detection of SARS-CoV-2 in exhaled air. Utilizing this approach, the study aims to utilize the test results extracted from the masks to identify risk factors for SARS-CoV-2 transmission and timing of infectious period in exposed people (pre-symptomatic, asymptomatic, and symptomatic).
Study NCT05524519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basic treatment
Description: 1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist.
Study NCT05524519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Basic treatment
Description: 1. Health education: Properly explain the causes and precautions of the patient and instruct the patient to rest regularly. In addition, care should be enhanced to avoid accidents.~2. The basic therapeutic drug is the use of one or more antidepressants, such as oral 5-hydroxytryptamine reuptake inhibitors, dual inhibitors of pentraxin and norepinephrine reuptake, noradrenergic and specific pentraxinergic antidepressants, pentraxin receptor balance antagonists, tricyclic antidepressants, etc. If there is significant sleep disturbance, benzodiazepines may be added temporarily. Dosing and dosage will be adjusted by a specialist.
Study NCT05524519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSA
Description: Four PSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
Study NCT05524519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TSA
Description: Four TSA selected in the first part of the study will be stimulated. According to the position of the acupoints, choose a needle of φ0.20\*1.5m or φ0.20\*1.2mm. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
Study NCT05524519 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CCA
Description: Acupoints: LR3 (Taichong), PC6 (Neiguan), SP6 (Sanyinjiao), and HT7 (Shengmen). PC6 and HT7 will use φ0.20\*1.2mm acupuncture needle. LR3 and SP6 will use φ0.20\*1.5m acupuncture needles. Press the needle to insert the acupoint vertically and retain it in the skin. After the intervention, the needle will be retained for 72 hours with a day of rest after removal. During needle retention, participants will be instructed to press the acupoints 3-4 times a day for about 1 minute each time, with the amount of stimulation as much as the patient can tolerate, at an interval of about 4 hours. A total of 10 treatment sessions will be performed for 6 weeks.
Study NCT06277856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer interaction/control
Description: This study was planned as a randomised controlled study with a two-group pretest and posttest design.
Study NCT04743440 — intervention group
Intervention type: DEVICE
Intervention: Bronchoscopic endotracheal intubation through a supraglottic airway device
Description: Prior to trial commencement, participants will be asked to watch a video demonstrating preparation and conduction of the procedure (bronchoscopic endotracheal intubation through a supraglottic airway device) in a patient not involved in the project. Afterwards they will submit an online test, examining knowledge of the procedure relating to the procedure checklist. After participants have watched the demonstration video and submitted the online test, trial investigator will demonstrate the procedure in the manikin; subsequently, they have the opportunity to train the procedure in the manikin with both Igel and Auragain - training estimated to take less than 30 minutes. Afterwards, they will have the opportunity to train the procedure on manikins, on their own discretion, as per usual standards for maintaining airway competence at the Anaesthesiology Department.
Study NCT05844735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet
Study NCT05844735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT05844735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin
Description: Tablet